Remote, I watched a video that explained how leronlimab was different than other CCR5 inhibitors. I don’t have a science background, but my takeaway is that leronlimab specifically targets the portion of the CCR5 cell where HIV (and potentially cancer and other diseases) attach to the cell, whereas other CCR5 inhibitors are deep buried and block everything from entering the CCR5 cell. Leronlimab allows for other drugs to be effective as it is not deep buried and block a specified target in the CCR5 receptor.

I watched this video a month or more ago, but you can find it on the CytoDyn website:

https://www.cytodyn.com/our-science/ccr5-and-cancer